why does nobody talk about CagriSema
why does nobody talk about CagriSema. I am not trying to be the "source?" guy. I would just like a source.
Why this compound is not simply another agonist, which is how it gets described everywhere else.
Amylin is co-secreted with insulin and signals satiety through its own receptor complexes. It is a different axis from the incretin system, not a parallel version of it. That is why the combination story is interesting: two mechanisms that address appetite differently, rather than more agonism at one receptor.
It is also why the dosing intuitions people bring from the semaglutide and tirzepatide boards do not transfer. Different receptors, different exposure-response, and no published schedule anybody here can reason from.
Reading the trial literature on this without misleading yourself.
Separate the monotherapy arms from the combination arms before you do anything else. They report different effect sizes and different tolerability, and almost every summary that circulates blends them.
Then read the tolerability tables rather than the headline. In combination work the interesting question is whether adding a second mechanism adds effect without adding proportionate side effects, and that question is answered in a table nobody quotes.
Finally, note the durations. Comparing a shorter readout here with a longer one from an established compound is not a comparison at all.
The honest state of the evidence on this board, since somebody should write it down.
Published clinical data exists and is genuinely interesting, particularly in combination. Independent purity data from members is thin — a handful of results across the whole site, against hundreds for the older molecules. Nothing containing this compound is approved as a standalone product, and research-use-only material is not approved for human use.
What follows practically: buy small if you buy at all, test what you get and post the result, and treat confident rankings against established compounds as the extrapolation they are. The board gets better as the log fills, and right now the log is nearly empty.
Please do not ask me what dose you should be on. I genuinely do not know and neither does anyone else here.
best — the order this archive was captured in
Independent purity data on this compound is sparse compared with the older molecules, simply because far fewer members have paid for testing. Sparse data means wide uncertainty, not a verdict.
Agreed that the monotherapy numbers look modest out of context and that the context is the whole story.
Combination and monotherapy arms must be read separately. Efficacy and tolerability both differ substantially between them and summaries routinely blur the two.
phase 3 data will change most of what gets said here
What does the tolerability table in that paper actually say?
Disagree — you are quoting a combination arm as though it were monotherapy. Those are different results.
nausea profile in the combination trials is the thing to read carefully
Not convinced. Amylin signalling is not a GLP-1 pathway and the mechanism you are proposing conflates them.
the interesting data is the combination, not the monotherapy
amylin analogue, different receptor family, different story
Complementary mechanisms are the rationale for pairing: satiety signalling alongside incretin signalling, rather than more agonism at the same receptor.
That is preclinical work and the thread is treating it as a human finding.
Right, and the tolerability data in the combination arms is the part worth reading properly rather than summarising.
Monotherapy arm or combination arm?
Same view — long-acting is the engineering achievement here, and it is why the molecule exists at all.
Asked a question here that turned out to be based on a mechanism confusion. Three people untangled it patiently.
- 1nausea profile in the combination trials is the thing to read carefully8 comments in this branch · started by u/zeynep_duarte